Trial Profile

A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter Study of Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype (SWIFT 02)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tucidinostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
Indications Follicular lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors Chipscreen Biosciences

15 Sep 2025 Planned primary completion date changed from 1 Dec 2031 to 1 Dec 2032.
15 Sep 2025 Status changed from not yet recruiting to recruiting.
05 May 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com